Perinatal exposure to progesterone, estradiol, or mifepristone affects sexual differentiation of behavior in opossums (Monodelphis domestica).
The effects of perinatal exposure to progesterone (P) and estradiol (E) on sexual differentiation of behavior and morphology were examined by treating male and female gray short-tailed opossums on postnatal day 8 with progesterone alone (P), P plus estradiol (E) (PE), the P receptor antagonist mifepristone/RU486 (MIF), or corn oil control (C) and gonadectomizing them before puberty. When given female hormone replacement therapy in adulthood and tested with intact stimulus males, MIF animals showed less female-typical aggressive threat behavior than animals in other treatment groups. Stimulus males scent marked in more tests involving females than males and in more tests involving MIF animals than animals in other treatment groups. Body weight was lower in females than in males and was lower in MIF animals than in animals in other treatment groups, and P females failed to show female-typical genital locks after copulation. Sexual receptivity was similar in males and females and, while not decreased by any perinatal hormone treatment, was higher in PE males than in animals of either sex in any treatment group. These findings suggest that perinatal exposure to P is associated with the organization of feminine threat behavior and the defeminization of attractivity, body weight and genital anatomy in this marsupial. Reasons for these findings and for why female sexual receptivity is enhanced by perinatal exposure to exogenous E only in an endogenous masculine environment are discussed.
Fadem
Barbara H
BH
Department of Psychiatry, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07101-5292, USA. fadem@umdnj.edu
Koester
Diana C
DC
Harder
John D
JD
D000818:Animals; D000831:Animals, Newborn; D002369:Castration / Q000523:psychology; D003307:Copulation / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology* / Q000502:physiology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000494:pharmacology* / Q000502:physiology; D020249:Hormone Replacement Therapy / Q000523:psychology; D008297:Male; D015735:Mifepristone / Q000494:pharmacology*; D009893:Opossums / Q000502:physiology*; D011374:Progesterone / Q000494:pharmacology* / Q000502:physiology; D012733:Sex Differentiation / Q000187:drug effects*; D012726:Sexual Behavior, Animal / Q000187:drug effects*
D012739:Gonadal Steroid Hormones; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol